Vir Biotechnology (VIR) Debt Ratio (2019 - 2025)

Name: Vir Biotechnology (VIR) Debt Ratio (2019 - 2025) | Business Quant
Creator: Business Quant

Vir Biotechnology recorded quarterly Debt Ratio of 0.01 in Q1 2025, up 16.56% quarter-over-quarter from 0.01 in Q4 2024.

Vir Biotechnology's Debt Ratio history runs 5 years deep, the most recent figure standing at 0.01 for Q1 2025.

In Q1 2025, Debt Ratio changed N/A year-over-year to 0.01; the TTM figure through Mar 2025 stood at 0.01 (changed N/A YoY), while the FY2024 annual figure was 0.01, changed N/A from the prior year.
Debt Ratio came in at 0.01 for Q1 2025 at Vir Biotechnology, up from 0.01 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.06 in Q3 2021 to a low of 0.01 in Q4 2024.
A 3-year average of 0.03 and a median of 0.02 in 2021 frame the typical range for Debt Ratio.
On a YoY basis, Debt Ratio climbed as much as 254.33% in 2021 and fell as far as 4.19% in 2021.
Vir Biotechnology's Debt Ratio stood at 0.06 in 2021, then tumbled by 79.72% to 0.01 in 2024, then gained by 16.56% to 0.01 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.01, 0.01, and 0.06 for Q1 2025, Q4 2024, and Q3 2021 respectively.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	0.18
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	1.41
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	0.05
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Vir Biotechnology	1.33 Bn	1.33 Bn	-	-

Download Data 🔒